NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy

Trial Profile

NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Neuromyelitis optica
  • Focus Therapeutic Use
  • Sponsors Nihon Pharmaceutical
  • Most Recent Events

    • 11 Apr 2017 Status changed from recruiting to completed.
    • 11 Jun 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 11 Jun 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top